VEGFA and neoplasm: The local tumour environment of patients with a lower response to bevacizumab may produce high levels of other factors that effectively compensate for the lack of available VEGF, thus mediating angiogenesis and oxidative damage evasion, alongside circulatory inflammation further promoting mCRC.